These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 21125049)

  • 1. Routine interferon-neutralising antibody testing in patients with relapsing-remitting multiple sclerosis.
    Foley P; Reilly P; Coulson A; O'Riordan JI
    J R Coll Physicians Edinb; 2010 Jun; 40(2):105-10. PubMed ID: 21125049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.
    Koch-Henriksen N; Sorensen PS; Bendtzen K; Flachs EM
    Mult Scler; 2009 May; 15(5):601-5. PubMed ID: 19299439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are ex vivo neutralising antibodies against IFN-beta always detrimental to therapeutic efficacy in multiple sclerosis?
    Sorensen PS; Koch-Henriksen N; Bendtzen K
    Mult Scler; 2007 Jun; 13(5):616-21. PubMed ID: 17548440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced effectiveness of long-term interferon-beta treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study.
    Boz C; Oger J; Gibbs E; Grossberg SE;
    Mult Scler; 2007 Nov; 13(9):1127-37. PubMed ID: 17967840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenic effects of recombinant interferon-beta therapy disrupt the JAK/STAT pathway in primary immune cells from patients with multiple sclerosis.
    Gavasso S; Gjertsen B; Anderssen E; Myhr K; Vedeler C
    Mult Scler; 2012 Aug; 18(8):1116-24. PubMed ID: 22287540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measuring and management of anti-interferon beta antibodies in subjects with multiple sclerosis.
    Farrell RA; Giovannoni G
    Mult Scler; 2007 Jun; 13(5):567-77. PubMed ID: 17548434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development.
    Hegen H; Millonig A; Bertolotto A; Comabella M; Giovanonni G; Guger M; Hoelzl M; Khalil M; Killestein J; Lindberg R; Malucchi S; Mehling M; Montalban X; Polman CH; Rudzki D; Schautzer F; Sellebjerg F; Sørensen PS; Deisenhammer F
    Mult Scler; 2014 Apr; 20(5):577-87. PubMed ID: 24009164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical effect of neutralizing antibodies to interferon beta that persist long after cessation of therapy for multiple sclerosis.
    van der Voort LF; Gilli F; Bertolotto A; Knol DL; Uitdehaag BM; Polman CH; Killestein J
    Arch Neurol; 2010 Apr; 67(4):402-7. PubMed ID: 20142519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical importance of neutralizing antibodies in relapsing-remitting multiple sclerosis.
    Namaka M; Pollitt-Smith M; Gupta A; Klowak M; Vasconcelos M; Turcotte D; Gong Y; Melanson M
    Curr Med Res Opin; 2006 Feb; 22(2):223-39. PubMed ID: 16466595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon-beta bioactivity measurement in multiple sclerosis: feasibility for routine clinical practice.
    van der Voort LF; Kok A; Visser A; Oudejans CB; Caldano M; Gilli F; Bertolotto A; Polman CH; Killestein J
    Mult Scler; 2009 Feb; 15(2):212-8. PubMed ID: 18805837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of Interferon-beta.
    Farrell R; Kapoor R; Leary S; Rudge P; Thompson A; Miller D; Giovannoni G
    Mult Scler; 2008 Mar; 14(2):212-8. PubMed ID: 17986510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response to interferon in multiple sclerosis is related to lipid-specific oligoclonal IgM bands.
    Bosca I; Villar LM; Coret F; Magraner MJ; Simó-Castelló M; Alvarez-Cermeño JC; Casanova B
    Mult Scler; 2010 Jul; 16(7):810-5. PubMed ID: 20538705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breakthrough disease during interferon-[beta] therapy in MS: No signs of impaired biologic response.
    Hesse D; Krakauer M; Lund H; Søndergaard HB; Langkilde A; Ryder LP; Sorensen PS; Sellebjerg F
    Neurology; 2010 May; 74(18):1455-62. PubMed ID: 20439848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fate of multiple sclerosis patients positive for neutralising antibodies towards interferon beta shifted to alternative treatments.
    Malucchi S; Capobianco M; Gilli F; Marnetto F; Caldano M; Sala A; Bertolotto A
    Neurol Sci; 2005 Dec; 26 Suppl 4():S213-4. PubMed ID: 16388361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis.
    Giovannoni G; Barbarash O; Casset-Semanaz F; Jaber A; King J; Metz L; Pardo G; Simsarian J; Sørensen PS; Stubinski B;
    Clin Ther; 2007 Jun; 29(6):1128-45. PubMed ID: 17692727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Important sources of variability in clinical studies of neutralizing antibodies against interferon beta.
    Hurwitz BJ
    J Neurol Sci; 2008 Sep; 272(1-2):8-19. PubMed ID: 18620708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
    Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M
    Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incorporation of an interferon-β neutralizing antibody assay into routine clinical practice.
    Farrell RA; Espasandin M; Lakdawala N; Creeke PI; Worthington V; Giovannoni G
    Mult Scler; 2011 Nov; 17(11):1333-40. PubMed ID: 21685230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical importance of neutralising antibodies against interferon-beta in patients with relapsing-remitting multiple sclerosis].
    Sørensen S; Koch-Henriksen NJ; Pedersen CR; Clemmesen KM; Bendtzen K; Frederiksen JL; Jensen K; Kristensen O; Petersen T; Rasmussen S; Ravnborg M; Stenager E;
    Ugeskr Laeger; 2004 Oct; 166(41):3606-9. PubMed ID: 15515467
    [No Abstract]   [Full Text] [Related]  

  • 20. Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study.
    Patti F; Amato MP; Trojano M; Bastianello S; Tola MR; Goretti B; Caniatti L; Di Monte E; Ferrazza P; Brescia Morra V; Lo Fermo S; Picconi O; Luccichenti G;
    Mult Scler; 2009 Jul; 15(7):779-88. PubMed ID: 19542262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.